Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30686999 | 1.00 | PDE4A (0.41) | PDE4APDE7APDE4DCYP1A2 | |
| SCHEMBL26968803 | 0.95 | PDE4A (0.37) | PDE4APDE7A | |
| SCHEMBL23068576 | 0.81 | — | — | |
| SCHEMBL22734114 | 0.81 | — | — | |
| SCHEMBL26968832 | 0.78 | — | — | |
| SCHEMBL22734118 | 0.78 | — | — | |
| SCHEMBL31571836 | 0.78 | LATS1 (0.32) | — | |
| SCHEMBL30639341 | 0.78 | LATS1 (0.32) | — | |
| SCHEMBL14734142 | 0.78 | LATS1 (0.32) | — | |
| SCHEMBL30639342 | 0.78 | LATS1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724195-B1 | SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| CN-117247395-A | PDE4B inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299497-B2 | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE5A, PDE4A, PDE7A | PDE4A 2/4885PDE7A 3/4885PDE4D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.